X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (184) 184
humans (180) 180
oncology (171) 171
female (141) 141
middle aged (89) 89
aged (77) 77
adult (74) 74
breast cancer (71) 71
breast neoplasms - pathology (59) 59
cancer (58) 58
metastasis (55) 55
male (48) 48
aged, 80 and over (42) 42
prognosis (41) 41
chemotherapy (38) 38
angiogenesis (37) 37
breast neoplasms - drug therapy (37) 37
treatment outcome (37) 37
breast neoplasms - genetics (32) 32
care and treatment (31) 31
analysis (30) 30
gene expression (28) 28
expression (27) 27
tumors (27) 27
disease-free survival (25) 25
neoplasm metastasis (25) 25
research (24) 24
survival (24) 24
antineoplastic agents - therapeutic use (23) 23
breast neoplasms - metabolism (22) 22
gene expression profiling (22) 22
hematology, oncology and palliative medicine (22) 22
therapy (22) 22
immunohistochemistry (21) 21
medicine & public health (20) 20
cancer therapies (19) 19
chemistry (18) 18
metallurgy (18) 18
neoplasm staging (17) 17
patients (17) 17
tamoxifen (17) 17
acyclic or carbocyclic compounds (16) 16
antineoplastic agents - administration & dosage (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
biomarkers (16) 16
breast neoplasms - mortality (16) 16
cancer research (16) 16
gene expression regulation, neoplastic (16) 16
genetic aspects (16) 16
medical research (16) 16
metastases (16) 16
organic chemistry (16) 16
carcinoma (15) 15
dose-response relationship, drug (15) 15
inflammatory breast cancer (15) 15
lymphatic metastasis (15) 15
pathology (15) 15
pharmacology & pharmacy (15) 15
cells (14) 14
oncology, experimental (14) 14
studies (14) 14
survival analysis (14) 14
antineoplastic agents - adverse effects (13) 13
biomarkers, tumor - genetics (13) 13
biomarkers, tumor - metabolism (13) 13
clinical trials (13) 13
drug administration schedule (13) 13
estrogen-receptor (13) 13
genes (13) 13
kaplan-meier estimate (13) 13
mutation (13) 13
research article (13) 13
trial (13) 13
administration, oral (12) 12
cell biology (12) 12
growth (12) 12
liver neoplasms - secondary (12) 12
lymphangiogenesis (12) 12
oligonucleotide array sequence analysis (12) 12
time factors (12) 12
breast neoplasms - blood (11) 11
development and progression (11) 11
endocrine therapy (11) 11
neoplastic cells, circulating - pathology (11) 11
neovascularization, pathologic (11) 11
progression (11) 11
prostate cancer (11) 11
solid tumors (11) 11
trastuzumab (11) 11
animals (10) 10
biomarkers, tumor - analysis (10) 10
breast-cancer (10) 10
circulating tumor cells (10) 10
cohort studies (10) 10
efficacy (10) 10
follow-up studies (10) 10
gene-expression (10) 10
heterocyclic compounds (10) 10
medicine, experimental (10) 10
metastatic breast cancer (10) 10
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (326) 326
French (8) 8
German (5) 5
Chinese (2) 2
Dutch (2) 2
Portuguese (2) 2
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2019, Volume 37, Issue 24, pp. JCO.19.00811 - 2181
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 406 - 414
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Neoplasia, ISSN 1476-5586, 2017, Volume 19, Issue 7, pp. 564 - 573
Abstract PURPOSE: Inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC... 
Oncology | ACTIVATION | METASTASIS | ONCOLOGY | KIT | BIOLOGY | MOLECULAR DETERMINANTS | EXPRESSION PROFILES | MUTATIONS | RHOC GTPASE | GASTROINTESTINAL STROMAL TUMORS | IMATINIB MESYLATE | Follow-Up Studies | Inflammatory Breast Neoplasms - pathology | Humans | Middle Aged | Cell Survival - genetics | Antineoplastic Agents - therapeutic use | Neoplasm Grading | Piperidines - pharmacology | Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors | Inflammatory Breast Neoplasms - drug therapy | Inflammatory Breast Neoplasms - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Benzimidazoles - therapeutic use | Disease Models, Animal | Cell Survival - drug effects | Gene Expression | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Inflammatory Breast Neoplasms - genetics | Platelet-Derived Growth Factor - pharmacology | Xenograft Model Antitumor Assays | Animals | Piperidines - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Cell Line, Tumor | Benzimidazoles - pharmacology | Aged | Mice | Mutation | Cell culture | Imatinib | Platelet-derived growth factor | Tumor cells | Invasiveness | Breast cancer | Inflammation | Gene expression | Growth factors | Metastases | Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Genomics | Cancer
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2012, Volume 134, Issue 3, pp. 1149 - 1159
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 23, pp. 2171 - 2179
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3239 - 3247
Journal Article
Future oncology (London, England), 04/2019
Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By... 
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 06/2019, Volume 15, Issue 17, pp. 1963 - 1973
Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By... 
APC activation | chemo-immunotherapy | PROTEIN | EFFICACY | Phase IIb trial | DOXORUBICIN | eftilagimod alpha | CHEMOTHERAPY | MOLECULES | TRIAL | LAG-3Ig | ONCOLOGY | IMP321 | metastatic breast cancer | ENGAGEMENT | immuno-oncology | LIGAND | LYMPHOCYTE-ACTIVATION GENE-3 | CD223
Journal Article
by Nik-Zainal, Serena and Davies, Helen and Staaf, Johan and Ramakrishna, Manasa and Glodzik, Dominik and Zou, Xueqing and Martincorena, Inigo and Alexanov, Ludmil B and Martin, Sancha and Wedge, David C and van Loo, Peter and Ju, Young Seok and Smid, Marcel and Brinkman, Arie B and Morganella, Sano and Aure, Miriam R and Lingjærde, Ole Christian and Langerød, Anita and Ringnér, Markus and Ahn, Sung-Min and Boyault, Sanine and Brock, Jane E and Broeks, Annegien and Butler, Adam and Desmedt, Christine and Dirix, Luc and nov, Serge and Fatima, Aquila and Foekens, John A and Gerstung, Moritz and Hooijer, Gerrit K. J and Jang, Se Jin and Jones, David R and Kim, Hyung-Yong and King, Tari A and Krishnamurthy, Savitri and Lee, Hee Jin and Lee, Jeong-Yeon and Li, Yilong and McLaren, Stuart and Menzies, Anew and Mustonen, Ville and O'Meara, Sarah and Pauporté, Iris and Pivot, Xavier and Purdie, Colin A and Raine, Keiran and Ramakrishnan, Kamna and Roíguez-González, F. Germán and Romieu, Gilles and Sieuwerts, Anieta M and Simpson, Peter T and Shepherd, Rebecca and Stebbings, Lucy and Stefansson, Olafur A and Teague, Jon and Tommasi, Stefania and Treilleux, Isabelle and van den Eynden, Gert G and Vermeulen, Peter and Vincent-Salomon, Anne and Yates, Lucy and Caldas, Carlos and van't Veer, Laura and Tutt, Anew and Knappskog, Stian and Tan, Benita Kiat Tee and Jonkers, Jos and Borg, Åke and Ueno, Naoto T and Sotiriou, Christos and Viari, Alain and Futreal, P. Anew and Campbell, Peter J and Span, Paul N and van Laere, Steven and Lakhani, Sunil R and Eyfjord, Jorunn E and Thompson, Alastair M and Birney, Ewan and Stunnenberg, Henik G and van de Vijver, Marc J and Martens, John W. M and Børresen-Dale, Anne-Lise and Richardson, Anea L and Kong, Gu and Thomas, Gilles and Stratton, Michael R and Los Alamos National Lab. (LANL), Los Alamos, NM (United States) and Onkologi och Patologi, MV and Familial Breast Cancer and Lund University and MEMEG and Oncology and Pathology, MV and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Lunds universitet and Familjär bröstcancer
Nature, ISSN 0028-0836, 2016, Volume 534, Issue 7605, pp. 47 - +
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2192 - 2204
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 51 - 64
Journal Article